Unlocking the Power of Patient Engagement within Clinical and Commercial
At the inaugural Patients as Partners Europe event, Duncan Arbour from inVentiv Health explores the ‘how’ and ‘when’ for involving patients within clinical and commercial to enhance the development an...
21 Jun 201712min
Patients Influencing Policy in the EU
Alastair Kent, Director of the Genetic Alliance UK, talks about how patients can and are influencing policy within the EU. The Patients as Partners Europe program seeks to understand and incorporat...
21 Jun 201731min
Immuno-Oncology 360°: Business Models for Complex Science by Dr Axel Hoos of GSK
Originally presented during the business aspects plenary session at Immuno-Oncology 360° 2017, Dr Axel Hoos of GSK discusses business models for complex science. Save the date for the 4th annual IO3...
21 Jun 201725min
Increasingly Critical Role of Predictive Biomarkers in Cancer Immunotherapy
Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the...
20 Jun 201723min
Innovative Ways of Patient Involvement in Medicines Development
Originally recorded at the inaugural Patients as Partners Europe event, held in London in February 2017. Patient, industry, and regulatory perspectives are provided by Alastair Kent of Genetic Allianc...
20 Jun 201754min
Addressing Clinical Challenges in Immuno-Oncology
Originally recorded during the 3rd annual Immuno-Oncology 360° in February 2017, this panel discussion addresses clinical challenges within immuno-oncology. One of the IO360° lead advisors, Dr James G...
20 Jun 201747min
Important Business Aspects of Immuno-Oncology: Issues and Controversies
Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspe...
20 Jun 201745min
Sequencing of Combination Agents in Immuno-Oncology with Dr Charles Drake
During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents." Dr Drake is Director, Genitourinary Onc...
16 Jun 201720min
